If you purchased or otherwise acquired Alcobra shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
Alcobra is a biopharmaceutical company that develops and markets oral drug candidates. On January 17, 2017, Alcobra revealed that the Company's attention deficit hyperactivity disorder drug, Metadoxine Extended Release, failed to reach its primary endpoint during a Phase 3 trial.
When this information was revealed to the investing public, the value of Alcobra declined, causing investors severe harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.